Almirall splits chairman and CEO roles
This article was originally published in Scrip
Executive Summary
The Spanish pharmaceutical company Almirall has appointed Eduardo Sanchiz, currently its chief executive of corporate development and finance, its new CEO. Mr Sanchiz will take up the position on 1 July. The move comes after the firm's current CEO and chairman, Jorge Gallardo, proposed to the board that these two roles be separated. Mr Sanchiz took up his current post at Almirall in 2004 after serving 22 years at Lilly working in a variety of roles in finance, marketing, business development and general management. Mr Gallardo was appointed the firm's CEO in 1997 and then chairman and CEO in 2001. He will continue as executive chairman.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.